Biodesix, Inc. Common Stock BDSX

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

BDSX hizo una agrupación de acciones (split inverso) de 1:20 el 15 de septiembre de 2025: cada 20 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• Zacks Investment Research 5 oct

  Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus

  Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.

  

• GlobeNewswire Inc. 3 sept

  Biodesix to Participate in Upcoming Investor Conferences

  Biodesix, Inc. announced its participation in three upcoming investor conferences in September 2026. The company reported Q2 2026 revenue of $26.9 million, representing 34% growth, with an 82% gross margin. Biodesix maintained its FY 2026 revenue guidance of $108-114 million, reflecting 25% growth expectations.

  

• GlobeNewswire Inc. 22 jul

  Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

  Biodesix, Inc. (Nasdaq: BDSX) announced it will release second quarter 2026 financial results on August 5, 2026 after market close, followed by a management conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update.